JP2006514012A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514012A5
JP2006514012A5 JP2004555329A JP2004555329A JP2006514012A5 JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5 JP 2004555329 A JP2004555329 A JP 2004555329A JP 2004555329 A JP2004555329 A JP 2004555329A JP 2006514012 A5 JP2006514012 A5 JP 2006514012A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
compound according
acceptable salt
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004555329A
Other languages
English (en)
Japanese (ja)
Other versions
JP4542906B2 (ja
JP2006514012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/032747 external-priority patent/WO2004048382A1/en
Publication of JP2006514012A publication Critical patent/JP2006514012A/ja
Publication of JP2006514012A5 publication Critical patent/JP2006514012A5/ja
Application granted granted Critical
Publication of JP4542906B2 publication Critical patent/JP4542906B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004555329A 2002-11-22 2003-11-10 キノリニル−ピロロピラゾール類 Expired - Fee Related JP4542906B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42889302P 2002-11-22 2002-11-22
PCT/US2003/032747 WO2004048382A1 (en) 2002-11-22 2003-11-10 Quinolinyl-pyrrolopyrazoles

Publications (3)

Publication Number Publication Date
JP2006514012A JP2006514012A (ja) 2006-04-27
JP2006514012A5 true JP2006514012A5 (enExample) 2006-12-14
JP4542906B2 JP4542906B2 (ja) 2010-09-15

Family

ID=32393478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004555329A Expired - Fee Related JP4542906B2 (ja) 2002-11-22 2003-11-10 キノリニル−ピロロピラゾール類

Country Status (28)

Country Link
US (2) US7265225B2 (enExample)
EP (1) EP1565471B1 (enExample)
JP (1) JP4542906B2 (enExample)
KR (1) KR101057282B1 (enExample)
CN (1) CN100345852C (enExample)
AT (1) ATE341550T1 (enExample)
AU (1) AU2003291643B2 (enExample)
BR (1) BR0315337A (enExample)
CA (1) CA2501322C (enExample)
CO (1) CO5570677A2 (enExample)
CR (1) CR7830A (enExample)
CY (1) CY1106283T1 (enExample)
DE (1) DE60308893T2 (enExample)
DK (1) DK1565471T3 (enExample)
EA (1) EA008387B1 (enExample)
EC (1) ECSP055807A (enExample)
EG (1) EG25822A (enExample)
ES (1) ES2273046T3 (enExample)
HR (1) HRP20050436B1 (enExample)
IL (1) IL168190A (enExample)
MX (1) MXPA05005432A (enExample)
NO (1) NO331403B1 (enExample)
NZ (1) NZ538942A (enExample)
PL (1) PL227840B1 (enExample)
PT (1) PT1565471E (enExample)
UA (1) UA80571C2 (enExample)
WO (1) WO2004048382A1 (enExample)
ZA (1) ZA200503121B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1567527A1 (en) * 2002-11-27 2005-08-31 Eli Lilly And Company Condensed pyrazolo derivatives
MX2008001020A (es) 2005-07-22 2008-03-25 Lilly Co Eli Un monohidrato de pirrolo[1-2-b]pirazol piridin quinolin substituido como inhibidor de factor de crecimiento de transformacion-beta (tgf-beta).
WO2007039151A1 (en) * 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
WO2008060371A1 (en) 2006-10-03 2008-05-22 Genzyme Corporation USE OF TGF-β ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
ES2435430T3 (es) * 2006-10-16 2013-12-19 Thesan Pharmaceuticals, Inc. Pirazolil tienopiridinas terapéuticas
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
PE20141066A1 (es) 2011-04-21 2014-09-05 Gilead Sciences Inc Compuestos de benzotiazol
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
PH12014500842A1 (en) 2012-04-20 2014-06-09 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
WO2014055998A1 (en) 2012-10-05 2014-04-10 Kadmon Corporation, Llc Human anti-vegfr-2/kdr antibodies
ES2791627T3 (es) 2012-11-12 2020-11-05 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico del cáncer colorrectal
TWI582083B (zh) 2014-10-07 2017-05-11 美國禮來大藥廠 胺基吡啶基氧基吡唑化合物
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
WO2018006870A1 (zh) * 2016-07-07 2018-01-11 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
US11111248B2 (en) 2017-03-17 2021-09-07 Hangzhou Solipharma Co., Ltd. Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof
CN110582279B (zh) * 2017-03-21 2023-07-14 杭州领业医药科技有限公司 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶,其制备方法和药物组合物
WO2019042383A1 (zh) * 2017-08-31 2019-03-07 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
WO2019137027A1 (zh) * 2018-01-12 2019-07-18 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
EP3827010B1 (en) 2018-07-23 2025-08-27 Brise Pharmaceuticals Co., Ltd. Bisphosphonate drug conjugates
CN113348167A (zh) 2018-12-27 2021-09-03 奈可萨斯医药有限公司 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020248908A1 (zh) * 2019-06-10 2020-12-17 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス,インコーポレイテッド Alk5阻害剤複合体およびその使用
AU2021223336A1 (en) 2020-02-19 2022-10-06 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
EP1206474B1 (en) * 1999-08-27 2004-05-26 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
ES2289116T3 (es) 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
EP1567528A1 (en) 2002-11-21 2005-08-31 Eli Lilly And Company Mixed lineage kinase modulators

Similar Documents

Publication Publication Date Title
JP2006514012A5 (enExample)
JP2009502743A5 (enExample)
JP2021191784A5 (enExample)
JP2005518413A5 (enExample)
JP2007522220A5 (enExample)
JP2009545527A5 (enExample)
JP2005523922A5 (enExample)
JP2020097577A5 (enExample)
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
JP2006515626A5 (enExample)
JP2005508905A5 (enExample)
JP2010526814A5 (enExample)
JP2012532874A5 (enExample)
JP2016006096A5 (enExample)
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
HRP20120803T1 (hr) Prolijekovi alkilatora fosforamidata
JP2004534850A5 (enExample)
JP2008535902A5 (enExample)
JP2019524883A5 (enExample)
JP2003503449A5 (enExample)
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
CA2501322A1 (en) Quinolinyl-pyrrolopyrazoles
JP2005536503A5 (enExample)
JP2008513510A5 (enExample)
JP2009520695A5 (enExample)